Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Pelthos Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Pelthos Therapeutics Inc.

PTHS

Pelthos Therapeutics Inc.

About Pelthos Therapeutics Inc.

Channel Therapeutics is a biotech company focused on developing non-opioid pain therapeutics targeting the NaV1.7 sodium channel. Its core programs include topical eye pain treatments, nerve block formulations for post-surgical pain, and therapies for neuropathic pain conditions like erythromelalgia and small fiber neuropathy. The company leverages proprietary molecules, advanced formulations, and strategic collaborations to address unmet pain management needs with potential for regulatory exclusivity and market impact.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Pelthos Therapeutics Inc.

1
1
Pelthos Therapeutics Inc. Pelthos Therapeutics Reports $10.9M Revenue in Q1 2026, Operating Loss of $13.1M

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Pelthos Therapeutics Inc. Pelthos Therapeutics Reports $43.3 Million Net Loss and $16.8 Million Revenue for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Pelthos Therapeutics Inc. Pelthos Therapeutics Reports $7.4M Revenue and $16.2M Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Pelthos Therapeutics Inc. Pelthos Therapeutics Reports Increased Losses and Financial Strain in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Pelthos Therapeutics Inc. Channel Therapeutics Reports Q1 2025 Financial Results, Faces Ongoing Challenges Amid Merger Agreement

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Pelthos Therapeutics Inc. Chromocell Therapeutics Reports $7.96 Million Net Loss for 2024, Completes IPO and Merger

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Pelthos Therapeutics Inc. Chromocell Therapeutics Reports Significant Asset Growth, Improved Cash Position, and Increased Operating Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments